36.97
+0.44
(1.22%)
Real-time:
3:17PM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 36.45 - 37.07 |
| 52 week | 30.87 - 44.53 |
| Open | 36.54 |
| Vol / Avg. | 161,450.00/303,730.00 |
| Mkt cap | 1.04B |
| P/E | 34.73 |
| Div/yield | - |
| EPS | 1.06 |
| Shares | 28.06M |
| Beta | 0.90 |
| Inst. own | 73% |
Events
Jul 22, 2013
Q2 2013 Integra LifeSciences Corporation Earnings Release
May 30, 2013
Integra LifeSciences Corporation at Deutsche Bank dbAccess Health Care Conference
- 11:20AM EDT -
May 21, 2013
Integra LifeSciences Corporation at UBS Global Healthcare Conference
- 2:30PM EDT -
May 14, 2013
Integra LifeSciences Corporation at Bank of America Merrill Lynch Health Care Conference
May 2, 2013
Q1 2013 Integra LifeSciences Corporation Earnings Conference Call
Apr 22, 2013
Q1 2013 Integra LifeSciences Corporation Earnings Release
Mar 19, 2013
Integra LifeSciences Corporation at Canaccord Genuity Musculoskeletal Conference
Mar 12, 2013
Integra LifeSciences Corporation at Barclays Healthcare Conference
Feb 26, 2013
Integra LifeSciences Corporation at Citi Global Healthcare Conference
Feb 26, 2013
Integra LifeSciences Corporation at RBC Capital Markets' Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -2.06% | 4.96% |
| Operating margin | -0.02% | 8.88% |
| EBITD margin | - | 23.03% |
| Return on average assets | -1.40% | 3.57% |
| Return on average equity | -3.16% | 8.16% |
| Employees | 3,500 | - |
| Carbon Disclosure Rating | - | - |
Address
311 Enterprise Drive
PLAINSBORO, NJ 08536
United States - Map
+1-609-2750500 (Phone)
+1-609-2755363 (Fax)
PLAINSBORO, NJ 08536
United States - Map
+1-609-2750500 (Phone)
+1-609-2755363 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Integra LifeSciences Corporation develops, manufactures and markets surgical implants and medical instruments. The Company's products are used to treat patients every year primarily in neurosurgery, orthopedics and general surgery.
Officers and directors
| Stuart M. Essig Ph.D. | Chairman of the Board | |
| Peter J. Arduini | President, Chief Executive Officer, Director | |
| John B. Henneman III | Corporate Vice President - Finance and Administration, Chief Financial Officer | |
| Padma Thiruvengadam | Chief Human Resources Officer, Corporate Vice President | |
| Judith E. O'Grady | Corporate Vice President - Global Regulatory Affairs, Corporate Compliance Officer | |
| John Mooradian | Corporate Vice President - Global Operations and Supply Chain | |
| Jerry E. Corbin | Corporate Vice President, Principal Accounting Officer, Corporate Controller | |
| Richard D. Gorelick | Corporate Vice President, General Counsel, Administration, Secretary | |
| Robert T. Davis Jr. | Corporate Vice President, President - Neurosurgery | |
| Brian Larkin | Corporate Vice President, President - Global Spine and Orthobiologics, and Head of Strategic Development |